Aggregator

From experience to expertise: Patients lead as authors in Cochrane's widely-used breast cancer review

1 year 3 months ago

Cochrane is an international, not-for-profit network of clinicians, patients and carers, researchers, and policy-makers creating high-quality healthcare evidence synthesises. Cochrane has a long and rich history of collaborating with healthcare consumers and this is the story of what breast cancer patients experienced when contributing to a Cochrane Review.  

In 1995, Nora Carbine and Liz Lostumbo, both former breast cancer patients, embarked on a transformative journey as attendees of the Leadership, Education, Advocacy, and Development (LEAD) program developed by the National Breast Cancer Coalition (US). Designed to equip patients with the necessary scientific and leadership essentials for becoming proactive advocates, this five-day initiative taught by notable scientists provided a platform for people with breast cancer to amplify their voices.  

One of the founders of LEAD and a course teacher was  Kay Dickerson MD, an epidemiologist and an active Cochrane member. Post-LEAD, Dr. Dickerson encouraged them to form a Journal Club, meeting monthly with her. Initially guided by Dr. Dickerson's article choices, the members eventually took the reins, presenting their findings on breast cancer research articles. Over a transformative two-year period, they developed their skills in scrutinizing research methods, assessing statistical validity, and distinguishing misinformation. Dr. Dickerson proposed to the group – would they be interested in leading on conducting a Cochrane systematic review on mastectomy to prevent breast cancer (prophylactic mastectomy)? 

A determined group of seven breast cancer advocates undertook the challenge to provide accessible information on prophylactic mastectomy for both patients and physicians, emphasizing the importance of informed decision-making. Guided by Dr. Dickerson and Davina Ghersi at Cochrane, they submitted their plan of study (Protocol) to Cochrane in 2000. They would gather at each other’s houses after work or on a Saturday morning and go through article after article, debating which ones to include and which to exclude. Despite one of the original members and driving force, Annette Drummond, becoming seriously ill with a recurrence of breast cancer, other members dropping out, and the abundance of evidence they had to wade through, the Cochrane review published in 2004, four years after this remarkable journey started.  

A unique feature of Cochrane reviews is that they are updated when new evidence is available. Classes in RevMan (Cochrane’s software for preparing and maintaining Cochrane and other systemic reviews) were taken and more people were added to the team, including an experienced reviewer. The first updated review was published in 2010. 

“Actress Angelina Jolie revealing her family history and her procedures coupled with the increasing availability of DNA testing, thrust the topic of mastectomy for breast cancer prevention into the limelight," says Liz Lostumbo. “We worried that women facing the decision of whether to undergo a prophylactic mastectomy might only encounter anecdotes in the popular media. We were particularly concerned about the lack of discussion concerning the quality of life for patients after mastectomy. The Cochrane review and its accompanying plain language summary became our means of addressing the critical gap in knowledge." 

For the third revision in 2018, they brought in more expertise and updated the wording, changing “prophylactic mastectomy” to “risk-reducing mastectomy”. The review is highly cited, has been made into a Cochrane Clinical Answer for clinicians, and has been included in three clinical guidelines. The plain language summary has been translated into 8 languages making it more accessible globally to patients making a decision and has been included in several Wikipedia articles.  

Nora and Liz note that they will hand other future updates to authors who can break the review into parts that ask more concise questions and produce more high-value conclusions – some of this work is already underway.  

“For us, the whole process of being the only group of patients to take on the responsibility of preparing a review and updating it was one of great satisfaction and pride,” says Nora Carbine. “We believe our work has helped thousands of women facing the decision of having a mastectomy to prevent breast cancer by providing evidence they need to be well informed to make their choice. We applaud Cochrane for giving us the opportunity and thank those who supported us in our endeavour.” 

Cochrane is extremely proud of Nora and Liz and all our patient and advocate volunteers. “While the work of Nora and Liz is extraordinary, it embodies the spirit of what Cochrane is trying to achieve.  We are proud to engage with patients to co-produce health evidence that is meaningful, easy to understand, and can be used for decision-making,” explains Richard Morley, Cochrane’s Consumer Engagement Officer. “The Cochrane Consumer Network has played a formal role since 1995 with over 2,000 members and Cochrane has a formal framework for involving patients, carers, and the public. While it’s likely most patients and caregivers aren’t as ambitious to author a Cochrane systematic review, we do hope this story is an inspiration for others to join our work.” From learning about health evidence and making informed health choices to volunteering to read over our plain language summaries on our volunteer hub Cochrane Engage, there are lots of ways you too can make a global impact on health! 

Tuesday, March 19, 2024 Category: The difference we make
Muriah Umoquit

无药物治疗用于新生儿气管内吸痰疼痛

1 year 3 months ago
无药物治疗用于新生儿气管内吸痰疼痛 关键信息 轻轻地将婴儿保持在膝盖弯曲的姿势(促进缩拢,当婴儿俯卧或脸朝上的仰卧或者头部偏向一侧并俯卧着肚子时即轻柔地将婴儿的手臂及腿放置靠近婴儿弯曲的身体中线位置)可能有效减轻机器通气新生儿气管内抽痰时的疼痛感。 什么是气管内抽痰? 气管内管是一种易弯曲的塑料管,透过鼻子或嘴巴放置于气管内,以保持使用机械性通气新生儿的呼吸道畅通(机械性呼吸器用于帮助新生儿呼吸)。 气管内管尖端需要被抽吸以保持清洁、通畅及无分泌物,好让婴儿能吸到氧气。气管内抽吸是常规护理程序。对婴儿来说是疼痛且不舒服的。 我们想要了解什么? 我们想了解如何在不使用药物的情況下减轻抽吸婴儿气管内时的疼痛。 我们做了哪些研究? 我们检索了医学资料库中的临床研究,寻找减轻婴儿气管内抽吸时疼痛的方法。 我们发现了什么? 我们发现八项研究,包括386名婴儿。 我们评估了六种不同方法在不使用药物的情况下减轻婴儿气管内抽吸疼痛的效果,例如: – 轻柔地将婴儿抱在促进缩拢的位置; – 熟悉的气味(母乳气味); – 使用糖溶液(蔗糖); – 使用挤出的母乳; – 白噪音; – 襁褓。 主要研究结果 在使用呼吸器的新生儿中 促进缩拢可能会减轻气管内抽吸过程中的疼痛。 熟悉的气味和白噪音在气管内抽吸过程中几乎没有或没有影响。使用挤出的母乳或口服蔗糖显示出,在减轻气管内抽吸过程中的疼痛方面,两者都没有...

Decision aids for people facing health treatment or screening decisions

1 year 3 months ago

A new Cochrane Library Editorial has been published about the history of a recently updated Cochrane review on healthcare decision aids and its implications for practice. There is also an accompanying podcast where you can hear the current lead author explain the need for the review and its latest findings in under four minutes.

Decision aids are one type of tool that can be used to support the process of shared decision making between patients and their health professionals, a key element of person-centred care and health system improvements. A major update to the landmark Cochrane review on decision aids has just been published with an analysis of 209 studies involving 107,698 participants. It provides clear evidence of the benefits of the use of decision aids over usual care across a huge array of health options, ranging from choices about cancer screening to decisions about major elective surgery.

An accompanying editorial describes the influence of this review on practice for over 20 years, with successive updates responding to the changing understanding of decision aids and shared decision-making over this time. The review has been referred to in more than 90 clinical practice guidelines and has been one of the most cited reviews published in the Cochrane Library for over a decade. 

With more convincing evidence of the benefits of using decision aids now available, the editorial discusses implications for practice and highlights some remaining challenges of implementing decision aids. This Cochrane review will continue to be updated and the authors hope to see the findings not only reflected in many guidelines but implemented across many health systems. 

  • Read the Cochrane Library editorial 
    Ryan RE, Hill S. Decision aids: challenges for practice when we have confidence in effectiveness. Cochrane Database of Systematic Reviews 2024, Issue 1. Art. No.: ED000164. DOI: 10.1002/14651858.ED000164.

  • Read the Cochrane review
     Stacey D, Lewis KB, Smith M, Carley M, Volk R, Douglas EE, Pacheco-Brousseau L, Finderup J, Gunderson J, Barry MJ, Bennett CL, Bravo P, Steffensen K, Gogovor A, Graham ID, Kelly SE, Légaré F, Sondergaard H, Thomson R, Trenaman L, Trevena L. Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews 2024, Issue 1. Art. No.: CD001431. DOI: 10.1002/14651858.CD001431.pub6.



  • Listen to the podcast
    Current lead author, Dawn Stacey from the University of Ottawa and Ottawa Hospital Research Institute in Canada, explains the need for the review and its latest findings in under 4 minutes.

  • Evidently Cochrane blog - Decision aids: helping people make better healthcare choices
    When faced with healthcare choices, how do we work out what to do? Decision aids can help, as can good conversations with our clinicians as part of shared decision-making, discussions that take into account clinical expertise, evidence and personal factors such as our preferences and circumstances. This blog includes Joanna’s story of her experience of making an important treatment decision but without the benefit of supportive discussions with her surgeon, plus some Cochrane evidence and useful UK resources.
Monday, January 29, 2024 Category: The difference we make
Muriah Umoquit

VIDEO: Cochrane's 2024 International Women’s Day Event

1 year 3 months ago

In celebration of 2024 International Women's Day (IWD), Cochrane is delighted to share a recording of an event showcasing a diverse panel of speakers discussing the IWD 2024 theme of #InspireInclusion

Tiffany Duque, Cochrane US Senior Officer, Panelist, and 2022 winner of the Anne Anderson Award says, "The 2024 IWD event was organized and hosted by our talented Cochrane US Mentees. This marks the third cohort through the Cochrane Mentoring program and the third IWD event. Hailing from 21 different countries, participants range from students to early career professionals, all poised for a bright future within Cochrane. We were delighted that they could once again host this cherished event. Thank you to everyone who attended and we invite everyone to watch the recording."

  • #InspireInclusion in health: What is the first step? from Dr Luis Gabriel Cuervo Amore
  •   Women in Science: Strategies to Call to Action from Dr Vivian Welch
  •  Mentee & Mentor: different languages, different cultures, and how to foster inclusion together from Kehinde Ayomide Agubosim and Dr Karen Gibbs

Paola Andrenacci, Cochrane US Mentor Program Coordinator, and lead for this event, shares her excitement, "We are thrilled about the turn out to this webinar and so happy we can expand the reach with this recording. It was wonderful to bring together this dynamic group to discuss issues of inspiring inclusion in healthcare. Their diverse perspectives and experiences can help us identify barriers to equity and work towards solutions benefiting everyone. I encourage everyone to watch and share the recording! A special thank you to our  Moderators Maya Abdelwahab, Claudia De Santis, Julia Costa-Maria Carolina Isaza."

Related resources:

 

Friday, March 8, 2024
Muriah Umoquit

对于接受非紧急髋关节或膝关节手术的患者来说,止血的最佳药物是什么?

1 year 3 months ago
对于接受非紧急髋关节或膝关节手术的患者来说,止血的最佳药物是什么? 关键信息 • 氨甲环酸(Tranexamic acid, TXA)可能是一种有效的药物,可在髋关节或膝关节置换手术期间帮助血液凝固,从而减少出血量以及需要输血的情况(用捐赠的血液替换失去的血液)。 • 使用高剂量的TXA,并以多种方式给药(例如,以片剂服用和手术结束时注射到关节内)似乎效果最佳。 • 当以片剂形式给予时,TXA的效果可能与静脉注射相当。 • 似乎没有证据显示,较高剂量的TXA会增加腿部血栓或其他危害的风险。 背景 在髋关节或膝关节手术期间止血的重要性是什么? 手术期间控制出血降低了病人发展成贫血并需要输血的可能性,这同时也减少了并发症的风险。当携带氧气的红血球(血红蛋白)数量低于正常水准时,就会出现贫血。这将导致疲劳、虚弱、晕眩、呼吸急促等症状,严重时可能危及性命。在手术期间预防失血有助于改善患者的手术结局、降低医疗成本,并保留供应有限的捐赠血液。 是否有可以帮助控制出血的药物? 许多研究已探讨特定药物,如TXA,是否有助于在手术期间最小化失血量。大多数研究测试不同剂量的药物、不同的给药方式以及在手术前、期间或术后不同的使用时间。 我们想知道什么? 我们想要了解药物是否能够减少接受髋关节或膝关节置换手术的病人的失血量,以及减少需要输血的情况。我们也想知道给予病人这种药物最有效的方式是什么。 我们做...

Cochrane seeks Cochrane Support & Training Officer

1 year 3 months ago

Specifications: Permanent – Full Time (1.0 FTE)
Salary:  £36,000 per Annum  
Location: (Remote – Flexible) Ideally based in the UK, Germany or Denmark. Candidates anywhere from the world will be considered; however, Cochrane’s Central Executive Team is only able to offer consultancy contracts outside these countries for 1-Year.
Closing date: 28 January 2024
 
Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into four directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

The Cochrane Support and Training Officer will work within the Cochrane Support Team, with special responsibility for providing training to internal Central Executive Team colleagues, Cochrane authors, and Cochrane Group staff. Training will focus on new Review Manager (RevMan) project and portfolio management features in 2024. The role also includes ongoing internal training responsibilities.   

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.  

You can expect:  

  • An opportunity to truly impact health globally.  
  • A flexible work environment  
  • A comprehensive onboarding experiences.
  • An environment where people feel welcome, heard, and included, regardless of their differences.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations, and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

  • For further information on the role and how to apply
  • The deadline to receive your application is 28th January 2024.
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples. 
  • Read our Recruitment Privacy Statement
Tuesday, January 23, 2024 Category: Jobs
Lydia Parsonson

正念强化育儿项目用于改善儿童及父母的结局

1 year 3 months ago
正念强化育儿项目用于改善儿童及父母的结局 关键信息 • 正念强化育儿培训项目可能改善一些儿童和家长的结局,包括儿童情绪和行为调整、育儿技能、父母抑郁和焦虑、育儿压力和家长正念。 • 当正念育儿培训与基于技能的育儿培训项目结合时,可能会减轻育儿压力。 • 目前的证据有限,需要更多研究来证实我们的发现。 儿童情绪及行为障碍 情绪及行为障碍在儿童中很常见,其特征为一系列随着时间推移高度稳定的外化或内化行为。它们是儿童时期功能障碍的重要因素,并预测了青春期及未来时期较差的心理社会、学业和就业功能。情绪及行为障碍的普遍性、稳定性和长期结果凸显了在行为模式较为容易修正的童年时期进行干预的重要性。 为什么是正念强化育儿培训? 育儿在儿童情绪及行为障碍的发展和/或维持中扮演着重要角色。传统的基于行为或技能的父母培训项目已被证明对一系列儿童和家长结局有积极的影响,但它们并不适合所有家长。造成这种情况的原因之一可能是父母的情感反应可能阻碍他们有效地运用育儿技能。纳入额外成分用于改善父母情绪反应的育儿项目可能会提高这些项目的结局。最近的研究显示,正念育儿干预可以通过改善父母调节情绪和压力的能力来促进父母和孩子的积极结局。因此,将正念育儿方法与传统的育儿培训项目相结合可能对父母及其孩子均有益。 我们想要发现什么? 我们探讨了包含正念元素的基于行为或技能的父母培训项目—“正念强化”育儿培训项目—是否可以改...

医生使用危险信号来检查新发现背痛的患者的椎体骨折情况

1 year 3 months ago
医生使用危险信号来检查新发现背痛的患者的椎体骨折情况 编辑注释:  请参阅https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014461.pub2/full以查看有关此主题的最新综述;此综述已替换。 本综述描述了对一种常见做法的认识,即,当患者向家庭医生、背痛诊所或可治疗新发背痛的急诊室进行求医时,检查脊髓损伤。 医生通常会问一些问题,并检查背部,以判断脊柱骨折的可能性。 检查骨折的原因是,普通背痛和骨折的治疗方法不同。 骨折通常通过X光片进行诊断,然后通过休息、使用背部支架和服用止痛药进行治疗。 常见的背痛可以通过运动、脊椎按摩推拿和服用止痛药来治疗;而X射线、计算机断层扫描(computed tomography, CT)和磁共振成像扫描对诊断没有帮助。 骨折是少见的,在向家庭医生求医的病例中,骨折导致背痛占1%至4.5%。 纳入数千名患者在内的8项研究描述了29个不同的问题和用于检查脊柱骨折的体检测试。 这29个测试中的大多数都不准确。 四个最好的问题询问了类固醇的使用(这会导致骨质疏松)、病人年龄(超过74岁会增加骨折风险)和近期创伤(比如跌倒)。 使用最佳问题的组合似乎可以提高准确性。 例如,在表达主诉是背痛时,74岁以上女性的病因更有可能是骨折。 在急诊室,最能判断脊椎骨折的迹象是背部疼痛...

口服灭活霍乱疫苗预防霍乱

1 year 3 months ago
口服灭活霍乱疫苗预防霍乱 关键信息 接种两剂全细胞重组疫苗((whole-cell plus recombinant vaccine, WC-rBS vaccine (Dukoral)),无论是否接种加强剂,均可在2年内减少霍乱病例。 两剂二价全细胞疫苗(bivalent whole-cell vaccine, BivWC vaccine (Shanchol))可在5年内减少霍乱病例。 单剂Shanchol可在2年内减少霍乱病例和严重脱水的霍乱病例。 这些疫苗被认为是安全的,所有组别都报告了类似的副作用。 还需要进一步研究,以评估单剂Shanchol和两剂Dukoral在5年随访期间的有效性。 我们没有发现关于其他BivWC疫苗(如Euvichol或Euvichol-Plus)的试验。然而,所有BivWC疫苗杀死霍乱弧菌的能力都是相同的。因此,将Shanchol试验的结果应用于Euvichol和Euvichol-Plus是合理的。 什么是霍乱? 霍乱是一种由 霍乱弧菌 引起的疾病。 人们吃了被霍乱弧菌污染的食物或喝了被霍乱弧菌污染的水就会被感染。霍乱遍布世界大部分地区,在卫生条件差或缺乏清洁水的地区,在人道主义危机期间尤其危险。霍乱患者可出现严重的腹泻,从而导致严重脱水。如果得不到治疗,许多人会死亡。 如何预防霍乱? 霍乱疫苗已研发多年。口服霍乱疫苗具有成本效益,且易于管理。在人...

血液透析过程中采取血液稀释治疗:哪些治疗可以减少凝血问题而不致出血

1 year 3 months ago
血液透析过程中采取血液稀释治疗:哪些治疗可以减少凝血问题而不致出血 研究问题是什么? 当患者使用透析机器来净化血液时(称为血液透析(haemodialysis, HD)),血液稀释治疗有助于预防血液在透析管中产生凝结。然而,治疗中过度稀释血液可能会导致出血问题。有多种不同药物可用于稀释血液,但目前尚不清楚哪一种是最好或最安全的选择。 我们做了什么? 本研究检索了截止2023年11月,有关于成人和儿童在HD期间血液稀释治疗的试验研究。我们采用GRADE对研究质量进行评估。 我们发现了什么? 我们发现了113项研究,涉及4535名接受HD治疗的患者。这些患者接受了不同形式的血液稀释治疗。接受的治疗方式是随机分配的(像抛硬币)。多数研究着眼于一种名为“低分子肝素”的治疗,与标准血液稀释治疗进行比较(称为“标准肝素”)。不幸的是,这些研究所纳入的患者数量较少,且仅针对在一到两个月治疗期间的凝血或出血风险。由于时间短以及研究的其他局限性,我们对研究结果非常不确定。目前的研究结果无法告诉我们,在透析治疗过程中,哪种血液稀释治疗方式更好或更安全。 结论 现有研究无法确定HD治疗期间稀释血液的最佳方式。 如果您发现此证据有帮助,请考虑向 Cochrane 捐款。我们是一家慈善机构,提供可获取的证据来帮助人们做出健康和护理决定。捐赠 作者结论:  包括 UFH 和 LMWH 在内的抗凝策...

孕妇维生素B 12 的补充

1 year 3 months ago
孕妇维生素B 12 的补充 关键信息 -孕期服用维生素B 12 补充剂的女性与未服用维生素B 12 补充剂的女性相比,在孕期或产后的维生素B 12 情况可能有所改善,包括出现更少的维生素B 12 缺乏和更高的维生素B 12 水平,但证据尚不确定。 -妊娠期间服用维生素B 12 补充剂对孕妇及其子女其他健康结局的影响尚不清楚。 公共卫生影响 维生素B 12 是维持人体血液和神经细胞健康的一种重要营养物质。维生素B 12 缺乏是一个重要的公共卫生问题,特别是在低收入和中等收入国家,孕妇和儿童负担沉重。孕期较低的维生素B 12 水平与一些不良妊娠结局风险的增加有关,如流产、胎儿在子宫内发育不良、婴儿大脑或脊髓的问题(称为神经管缺陷),以及婴儿维生素B 12 水平较低。 孕期补充维生素B 12 可能有助于改善母婴健康和营养状况。然而,这还没有经过充分的评价,并且维生素B 12 不是世界卫生组织(WHO;联合国负责国际公共卫生的专门机构)给孕期妇女推荐补充剂的一部分。 我们想知道什么? 我们想知道在孕期服用维生素B 12 补充剂是否会改善妇女及其婴儿的健康和营养状况。 我们做了什么? 我们检索了关于孕期补充维生素B 12 的临床试验。我们对试验结果进行了比较和总结,并根据试验方法和规模等因素对资料的可信度进行了评估。 我们发现了什么? 我们纳入了5项涉及984名孕妇的试验。包括609名孕妇...